89bio, Inc. (ETNB) Misses Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to 89bio, Inc. (ETNB) Misses Q2 EPS by 21c
August 7, 2025 4:05 PM EDT
ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH)
ENTRUST Phase 3 topline data in severe hypertriglyceridemia (SHTG) expected in 1Q 2026
Cash, cash equivalents, and marketable securities totaled $561.2 million as of June 30, 2025
SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today... More
